Nordic Life Science
Using DNA origami – DNA-based design of precise nanostructures – scientists at Karolinska Institutet in Sweden and at University of Oslo, Norway, have been able to demonstrate the most accurate
The company has announced organizational changes, including the development of R&D and commercial units in its biopharmaceuticals area and in oncology. In addition, three senior executives leaves the company and
Noora Männikkö is a software designer focusing on healthcare applications. She likes working with something that can have a societal impact and she believes that digital health tools bring a
Bristol-Myers Squibb (BMS) and Celgene have announced that they have entered into a definitive merger agreement under which BMS will acquire Celgene in a cash and stock transaction with an
Based on an application by Denmark’s Ministry of Health, the Board of Directors of the Novo Nordisk Foundation has approved a framework grant of DKK 990 million (€133 million) over 4.5
The company is launching Rexulti (brexiprazole) for the treatment of adult patients with schizophrenia in Switzerland from 1 January 2019. The launch is the first in a sequence that will
Sponsored Content
Drug & Device development
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
The company initiates a phase II-study (proof of concept-study) with the compound Lu AF11167 to confirm its potential as treatment of patients with schizophrenia who are experiencing persistent negative symptoms.
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who
The Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either
The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer. The
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. A
Using DNA origami – DNA-based design of precise nanostructures – scientists at Karolinska Institutet in Sweden and at University of Oslo, Norway, have been able to demonstrate the most accurate
Latest news
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
Our region is filled with life science activity. We take a closer look at what´s going in our Nordic cities when it comes to life science efforts, progress and challenges.
In focus – Nordic cities
Nordic Life Science
The latest clinical trials
The company announces that it has completed patient enrollment in its multi-centre, Phase II, randomized, double-blind, placebo-controlled study to explore the efficacy and safety of Sevuparin infusion for the management
The company initiates a phase II-study (proof of concept-study) with the compound Lu AF11167 to confirm its potential as treatment of patients with schizophrenia who are experiencing persistent negative symptoms.
The first patient has been dosed in an investigator-initiated phase II trial of bemcentinib, a selective, potent and orally bio-available AXL inhibitor, in patients with high-risk myelodysplastic syndrome (MDS) who
The Phase III OLYMPUS and ROCKIES trials for roxadustat each met their primary efficacy endpoints for the treatment of patients with anaemia in chronic kidney disease (CKD) that are either
The company applied today with the Swedish Medical and Pharmaceutical Agency for initiation of a phase I clinical trial of the contrast agent SpagoPix (SN132D) in patients with breast cancer. The
Regulatory approvals have been obtained for the first clinical study of ATOR-1015 and patient recruitment can now be initiated. ATOR-1015 is a wholly-owned drug candidate developed for tumor-directed immunotherapy. A
The company has submitted its first national Clinical Trial Application (CTA) to the Food and Drug Administration (FDA) in the US for the start of their Xplore trial for Xlucane. This
All patients in the company’s phase I part of the CANFOUR clinical trial have completed the formal safety evaluation phase of the trial and no dose limiting toxicities (DLTs) were
Nordic Nanovector announces that updated results from its LYMRIT 37-01 Phase 1/2 clinical study of Betalutin (177Lu-lilotomab-satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin’s lymphoma (R/R iNHL) have been presented in
The company has presented a comprehensive analysis of monotherapy data from its BGBC003 clinical trial (NCT02488408) with selective AXL inhibitor bemcentinib in patients with relapsed/refractory Acute Myeloid Leukaemia (AML) or
The company is partnering with Beijing University Cancer Hospital and Konica Minolta in a clinical trial to assess the efficacy of scalp cooling for chemotherapy-induced hair loss in women with
LIDDS adds two major university clinics in Lithuania to its ongoing Phase IIb study, the National Cancer Institute in Vilnius and the University Clinic of Kaunas. The two clinics are
The company has announced new data from the CERTiFy (CERAMENT Treatment of Tibia Plateau Fracture defects) study comparing CERAMENT|BVF with autologous iliac bone graft (autograft). “Successfully completing the ground-breaking CERTiFy study, to demonstrate
A1M Pharma announces that the Swedish Medical Products Agency has granted permission to start a clinical Phase I study of ROSgard – a drug candidate developed to prevent Acute Kidney
The company announces that the dosing of patients in its first trial PP-CT01, studying the safety and tolerability of XEN-D0501 in patients with type 2 diabetes, was completed. XEN-D0501 is
The latest research news from the Nordic region
Science Article
Using DNA origami – DNA-based design of precise nanostructures – scientists at Karolinska Institutet in Sweden and at University of Oslo, Norway, have been able to demonstrate the most accurate
New results could help select patients who might benefit most from BAFF inhibitors for autoimmune diseases. Many autoimmune conditions such as multiple sclerosis and rheumatoid arthritis are more common in
Researchers at Karolinska Institutet present a new method for analyzing how instructions in the genome control how our genes are activated in individual cells. The results give new insights into
Scientists at the Technical University of Denmark upend conventional wisdom about introducing new genes into bacteria. Why do some foreign genes work well in a new host and some do
University of Gothenburg researchers find that weight-bearing bones may help regulate body fat. Do you use a standing desk at work? They’re popular in part because studies show higher risks
Elypta’s co-founder and Chief Scientific Officer, Francesco Gatto, has been named Pioneer of the Year at MIT Technology Review’s European Innovators Under 35 Summit in Paris. The co-founder of the Swedish liquid-biopsy startup Elypta